A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025
By Skylar Jeremias
ArticleIn 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.